Evidence map›Paper›PMID 34638539›Full record

ArticleInternational journal of molecular sciences2021

Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature.

Enrica Torretta, Micaela Garziano, Mariacristina Poliseno, Daniele Capitanio, Mara Biasin, Teresa Antonia Santantonio, Mario Clerici, Sergio Lo Caputo, Daria Trabattoni, Cecilia Gelfi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Enrica TorrettaIRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.ORCID 0000-0002-6374-3325
Micaela GarzianoDipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, 20122 Milan, Italy.
Mariacristina PolisenoUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0002-9896-489X
Daniele CapitanioDepartment of Biomedical Sciences for Health, University of Milan, 20090 Segrate, Italy.ORCID 0000-0001-7701-728X
Mara BiasinDipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, 20157 Milan, Italy.ORCID 0000-0003-3671-4235
Teresa Antonia SantantonioUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Mario ClericiDipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0001-5920-6191
Sergio Lo CaputoUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Daria TrabattoniDipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, 20157 Milan, Italy.ORCID 0000-0001-9535-3359
Cecilia GelfiIRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.ORCID 0000-0002-2996-6912
University of Milan · ITUniversity of Foggia · ITIstituto Ortopedico Galeazzi · IT

Funding

Fondazione Cariplo 2020-1795
6 · The paper itself

Abstract

The reason behind the high inter-individual variability in response to SARS-CoV-2 infection and patient's outcome is poorly understood. The present study targets the sphingolipid profile of twenty-four healthy controls and fifty-nine COVID-19 patients with different disease severity. Sera were analyzed by untargeted and targeted mass spectrometry and ELISA. Results indicated a progressive increase in dihydrosphingosine, dihydroceramides, ceramides, sphingosine, and a decrease in sphingosine-1-phosphate. These changes are associated with a serine palmitoyltransferase long chain base subunit 1 (SPTLC1) increase in relation to COVID-19 severity. Severe patients showed a decrease in sphingomyelins and a high level of acid sphingomyelinase (aSMase) that influences monosialodihexosyl ganglioside (GM3) C16:0 levels. Critical patients are characterized by high levels of dihydrosphingosine and dihydroceramide but not of glycosphingolipids. In severe and critical patients, unbalanced lipid metabolism induces lipid raft remodeling, leads to cell apoptosis and immunoescape, suggesting active sphingolipid participation in viral infection. Furthermore, results indicated that the sphingolipid and glycosphingolipid metabolic rewiring promoted by aSMase and GM3 is age-dependent but also characteristic of severe and critical patients influencing prognosis and increasing viral load. AUCs calculated from ROC curves indicated ceramides C16:0, C18:0, C24:1, sphingosine and SPTLC1 as putative biomarkers of disease evolution.

Indexed as

AdultAgedAged, 80 and overCOVID-19FemaleHumansLipidomicsMaleMiddle AgedPrognosisSARS-CoV-2Severity of Illness IndexSphingolipidsSphingomyelinsYoung AdultSphingolipidsSphingomyelinsacid sphingomyelinasecaspase 3COVID-19COVID-19 severityfrailtymass spectrometryserine palmitoyltransferasesphingolipids

Identifiers

PMID34638539
PMCPMC8508132
OpenAlexW3201225897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.